Evaluating the economic benefits of complex interventions: accounting for non-health effects of genomic-based diagnostic information

Presenter: Martin Eden

Thursday 15th August 2.30pm–3.30pm
Seminar Room 515, Level 5
207 Bouverie Street, Carlton

The receipt of diagnostic information from a genomic test can result in both health and non-health impact. Current applications of cost-effectiveness analysis (CEA) do not take into account non-health value deriving from genomic-based diagnostic information. For my PhD, I undertook a meta-synthesis of qualitative evidence to develop a taxonomy of this non-health value. This provided a starting point for further qualitative work to design a discrete choice experiment (DCE). Findings from the DCE demonstrated that people are willing to trade-off between health and non-health outcomes of genomic test information. The quantification of these trade-offs could be used to refine CEA methods in this context. This work has implications for the economic evaluation of complex precision medicine interventions comprising a diagnostic component.